Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Raw Materials (2023 - 2025)

Tg Therapeutics has reported Raw Materials over the past 3 years, most recently at $4.1 million for Q3 2025.

  • Quarterly results put Raw Materials at $4.1 million for Q3 2025, up 134.08% from a year ago — trailing twelve months through Sep 2025 was $4.1 million (up 134.08% YoY), and the annual figure for FY2024 was $28.2 million, up 327.7%.
  • Raw Materials for Q3 2025 was $4.1 million at Tg Therapeutics, down from $4.1 million in the prior quarter.
  • Over the last five years, Raw Materials for TGTX hit a ceiling of $28.2 million in Q4 2024 and a floor of $24000.0 in Q1 2023.
  • Median Raw Materials over the past 3 years was $1.7 million (2024), compared with a mean of $4.9 million.
  • Peak annual rise in Raw Materials hit 7129.17% in 2024, while the deepest fall reached 41.21% in 2024.
  • Tg Therapeutics' Raw Materials stood at $6.6 million in 2023, then skyrocketed by 327.7% to $28.2 million in 2024, then tumbled by 85.58% to $4.1 million in 2025.
  • The last three reported values for Raw Materials were $4.1 million (Q3 2025), $4.1 million (Q2 2025), and $4.1 million (Q1 2025) per Business Quant data.